套细胞淋巴瘤治疗方案的选择和建议
王华庆
【期刊名称】《白血病·淋巴瘤》
【年(卷),期】2012(021)007
【摘要】Intensive multidrug regimens,such as rituximah plus fractionated cyclophsphamide,vincristine,doxorubicin,and dexamethasone(R-HyperCVAD),are now being used to improve outcomes in patients with mantle cell lymphoma(MCL).In addition to these combinations,novel targeted agents,including bortezomib,bendamustine,and lenalidomide,are also being integrated into the treatment paradigm.Given the wide array of therapies available,making and implementing treatment decisions has become a complex process,requiring interdisciplinary collaboration.This article discussesed the pharmacist's role in this collaboration,as well as the administration of standard and novel therapies for MCL and the management of treatment related toxicities.%套细胞淋巴瘤的治疗近年来受到广泛重视.以R-HyperCVAD为代表的多药联合方案大大提高了套细胞淋巴瘤的疗效和生存率.新的抗肿瘤药物和靶向药物包括硼替佐米、苯达莫司汀和来那度胺等已经被应用到新的方案中,开阔了该肿瘤治疗的新视野.文章在介绍套细胞淋巴瘤治疗新进展的同时,对临床上常见的疑惑和问题给予了分析和解答.【总页数】5页(385-389)
【关键词】淋巴瘤,膜细胞;靶向治疗;抗肿瘤新药